Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:28:47 EDT Tue 06 Oct 2026
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z0.11.26·1.610.11.385-0.075-5.1301.33558621.4698  1.48  1.362.2299  0.8516:04:0408:4515 min RT 2¢

Recent Trades - Last 10 of 862
Time ETExPriceChangeVolume
16:04:04Z1.40-0.051
16:04:04Z1.40-0.051
16:00:13Z1.40-0.051
16:00:13Z1.40-0.051
16:00:13Z1.40-0.051
16:00:13Z1.40-0.051
15:59:52Z1.385-0.06511
15:59:51Z1.385-0.06550
15:59:51Z1.385-0.06550
15:59:51Z1.385-0.06513

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-06 08:45U:NNVCNews ReleaseNanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
2026-10-05 08:45U:NNVCNews ReleaseNanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
2026-09-29 08:45U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
2026-09-28 08:45U:NNVCNews ReleaseClinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
2026-09-23 08:30U:NNVCNews ReleasePhase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
2026-09-15 09:25U:NNVCNews ReleaseClinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
2026-09-15 09:00U:NNVCNews ReleaseA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
2026-09-08 08:30U:NNVCNews ReleaseClinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
2026-08-31 08:30U:NNVCNews ReleaseWhile Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
2026-08-18 08:30U:NNVCNews ReleaseThe Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
2026-08-10 08:30U:NNVCNews ReleaseNanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
2026-07-28 08:30U:NNVCNews ReleaseNanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
2026-07-24 08:00U:NNVCNews ReleaseNanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
2026-07-22 08:30U:NNVCNews ReleaseAs Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
2026-07-13 09:27U:NNVCNews ReleaseAs Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
2026-07-08 08:30U:NNVCNews ReleaseResearch Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
2026-07-06 08:30U:NNVCNews ReleaseAs the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
2026-06-29 08:30U:NNVCNews ReleaseUS FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
2026-06-22 09:30U:NNVCNews ReleaseNanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
2026-06-15 08:30U:NNVCNews ReleaseAs the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo